Longevity science
Cellular reprogramming is being tested in people, but reversing human ageing is unproven. Life Biosciences reports the first dosing of ER-100 in a Phase 1 trial for optic neuropathy. The trial has permission to study safety and possible vision benefits. Nobody has approval to sell an anti-ageing treatment, and whole-body rejuvenation has not been shown.
Research snapshot · updated Nov 12, 2026
State of the art (2026)
In June 2026 longevity science crossed from preclinical promise into the clinic. Life Biosciences dosed the first patient with ER-100 - the first FDA-cleared partial epigenetic reprogramming therapy (OSK gene therapy for optic neuropathies) - on 9 June, while Altos Labs (still private, Bezos- and Milner-backed) edged towards its own trials. Retro Biosciences raised at a $1.8B valuation in May and is running RTR242, an autophagy pill in Alzheimers, with first data due around August. Loyals canine drug LOY-002 has FDA acceptance of two of three technical sections, eyeing a 2026 launch. The unresolved question remains whether reversing a biological-age clock translates into clinical benefit; no geroprotector is yet approved on an aging indication.
Explore the deeper analysis in CanaryIQ
Explore what is covered below. These previews show the structure; log in to read the full analysis.
Signal stack
Evidence stacked leading → lagging
9 signals
Signal stack
Evidence stacked leading → lagging
Technology-native KPIs
Metrics that predict trajectory, tracked over time
4 tracked
Technology-native KPIs
Metrics that predict trajectory, tracked over time
Landscape map
Who builds what, and who depends on whom
187 players · 6 layers
Landscape map
Who builds what, and who depends on whom
Catalyst calendar
Dated events that will move the position
4 ahead
Catalyst calendar
Dated events that will move the position
Technology roadmap
Milestones on the path to maturity
8 milestones
Technology roadmap
Milestones on the path to maturity
Watchlists
Companies, people and papers, each with a condition for removing it
20 · 3
Watchlists
Companies, people and papers, each with a condition for removing it
Decision frameworks
What our view means for your job
Locked
Decision frameworks
What our view means for your job
Thesis changelog
When our view changed, and why
7 updates
Thesis changelog
When our view changed, and why
Change our mind
3 disconfirming conditions
You've read the verdict. The file is much deeper.
The full signal stack, technology-native KPIs tracked over time, the landscape of who depends on whom, the dated catalyst calendar, decision frameworks for every desk, live watchlists and a record of every time our view on Longevity science has changed. All of it is in CanaryIQ.